Vontobel Holding Ltd. Takes $222,000 Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Vontobel Holding Ltd. bought a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund bought 9,500 shares of the biopharmaceutical company’s stock, valued at approximately $222,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in TGTX. NBC Securities Inc. raised its position in shares of TG Therapeutics by 58.9% in the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 485 shares during the last quarter. Ashton Thomas Private Wealth LLC acquired a new stake in shares of TG Therapeutics in the second quarter worth $35,000. ORG Wealth Partners LLC acquired a new position in shares of TG Therapeutics in the 3rd quarter valued at about $53,000. DekaBank Deutsche Girozentrale purchased a new position in TG Therapeutics during the first quarter valued at approximately $58,000. Finally, Lazard Asset Management LLC purchased a new position in shares of TG Therapeutics during the 1st quarter valued at approximately $91,000. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

TG Therapeutics Trading Down 4.6 %

Shares of TGTX opened at $23.13 on Thursday. TG Therapeutics, Inc. has a 52-week low of $6.77 and a 52-week high of $26.41. The stock has a market cap of $3.57 billion, a PE ratio of 102.70 and a beta of 2.21. The firm’s fifty day moving average is $23.32 and its two-hundred day moving average is $19.53. The company has a quick ratio of 2.83, a current ratio of 3.58 and a debt-to-equity ratio of 0.58.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.08. The firm had revenue of $73.47 million for the quarter, compared to analyst estimates of $65.92 million. TG Therapeutics had a net margin of 27.60% and a return on equity of 57.73%. TG Therapeutics’s quarterly revenue was up 357.0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.34) earnings per share. Research analysts forecast that TG Therapeutics, Inc. will post 0.13 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. HC Wainwright restated a “buy” rating and issued a $49.00 price target on shares of TG Therapeutics in a research note on Wednesday, September 18th. B. Riley increased their price objective on shares of TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Finally, The Goldman Sachs Group boosted their target price on shares of TG Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, TG Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $31.83.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.